Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Collagenase (marketed as Santyl) is a topical enzymatic debriding agent used to remove necrotic (dead) tissue from chronic skin ulcers and severely burned areas. The active ingredient, collagenase, is an enzyme derived from the fermentation of *Clostridium histolyticum*. Its mechanism of action involves selectively breaking down and digesting denatured or damaged collagen in necrotic tissue while sparing healthy granulation tissue. This selective enzymatic debridement promotes wound healing by clearing barriers to new tissue growth and facilitating the formation of granulation tissue and subsequent re-epithelialization. Collagen accounts for about 75% of the dry weight of skin; thus, its targeted removal in nonviable tissues accelerates wound bed preparation for healing[1][2][3][6]. Collagenase Santyl Ointment is FDA-approved for use in adults with chronic dermal ulcers and severe burns[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on collagenase.